Elalfy Mohamed, Elsawah Kareem, Maqsood Sundas, Jordan Nigel, Hassan Mansour, Zaki Ahmed, Gatzioufas Zisis, Hamada Samer, Lake Damian
Corneoplastic Unit and Eye Bank, Queen Victoria Hospital NHS Foundation Trust, East Grinstead, UK.
Cornea Unit, Research Institute of Ophthalmology, Giza, Egypt.
Ophthalmol Ther. 2025 Feb;14(2):413-432. doi: 10.1007/s40123-024-01083-x. Epub 2025 Jan 4.
This study compared the clinical outcomes of allogenic cultured limbal epithelial transplantation (ACLET) and cultivated oral mucosal epithelial transplantation (COMET) in the management of limbal stem cell deficiency (LSCD).
Forty-one COMET procedures in 40 eyes and 69 ACLET procedures in 54 eyes were performed in the Corneoplastic Unit of Queen Victoria Hospital, East Grinstead. Data were examined for demographics, indications, ocular surface stability, absence of epithelial defect, ocular surface inflammation, visual outcomes, and intra- and postoperative complications.
Kaplan-Meier analysis showed that patients in the ACLET group with longer follow-up had a significantly higher graft survival rate (81.7%, n = 56) than the COMET group (60.7%, n = 25) and the difference was statistically significant (p = 0.01). In the COMET group, there was no statistically significant improvement in the visual acuity (VA) while in the ACLET group there was statistically significant improvement in the final VA. Elevated intraocular pressure (IOP) developed in 9 eyes (22.0%) in the COMET group and in 18 eyes (26.1%) in the ACLET group; infection developed in 4 eyes (9.8%) in the COMET group and in 10 eyes (14.5%) in the ACLET group; and perforation or melting happened in 4 eyes (9.8%) in the COMET group and in 1 eye (1.4%) in the ACLET group. Postoperative immunosuppression complications were noted in 9 eyes (13.0%) in the ACLET group. No graft rejection was observed in either group.
Both ACLET and COMET are effective therapeutic procedures for managing advanced and bilateral cases of LSCD. Although COMET has lower graft survival rate than ACLET, it does not mandate systemic immunosuppression therapy to protect against potential graft rejection.
本研究比较了同种异体培养角膜缘上皮移植术(ACLET)和培养口腔黏膜上皮移植术(COMET)治疗角膜缘干细胞缺乏症(LSCD)的临床效果。
在东格林斯特德维多利亚女王医院角膜整形科,对40只眼进行了41例COMET手术,对54只眼进行了69例ACLET手术。检查了患者的人口统计学资料、手术指征、眼表稳定性、上皮缺损情况、眼表炎症、视力结果以及手术中和术后并发症。
Kaplan-Meier分析显示,随访时间较长的ACLET组患者的移植存活率(81.7%,n = 56)显著高于COMET组(60.7%,n = 25),差异具有统计学意义(p = 0.01)。COMET组的视力(VA)无统计学意义的改善,而ACLET组的最终视力有统计学意义的改善。COMET组有9只眼(22.0%)出现眼压(IOP)升高,ACLET组有18只眼(26.1%)出现眼压升高;COMET组有4只眼(9.8%)发生感染,ACLET组有10只眼(14.5%)发生感染;COMET组有4只眼(9.8%)出现穿孔或融化,ACLET组有1只眼(1.4%)出现穿孔或融化。ACLET组有9只眼(13.0%)出现术后免疫抑制并发症。两组均未观察到移植排斥反应。
ACLET和COMET都是治疗晚期双侧LSCD病例的有效治疗方法。虽然COMET的移植存活率低于ACLET,但它不需要全身免疫抑制治疗来预防潜在的移植排斥反应。